CDA | Evidence Driven
CDA | Evidence Driven

Lenvima for Renal Cell Carcinoma – Details

Details

Files
Generic Name:
Lenvatinib
Project Status:
Complete
Therapeutic Area:
Renal Cell Carcinoma (RCC)
Manufacturer:
Eisai Limited
Brand Name:
Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0140 -000
Performance Metric:
Achieved
Strength:
4mg and 10mg
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma (RCC)
Funding Request:
In combination with everolimus for the treatment of patients with advanced or metastatic, clear-cell RCC following one prior VEGF-targeted therapy.
Sponsor:
Eisai Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lenvatinib (Lenvima) RCC – pERC Final Recommendation Final Recommendation January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC - Final Clinical Guidance Report Guidance Reports January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC - Final Economic Guidance Report Guidance Reports January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC - pERC Initial Recommendation Initial Recommendation November 1, 2018 View PDF
Lenvatinib (Lenvima) RCC – PAG Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC – Submitter Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC – Patient Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC – Clinician Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC – Patient COI Declarations COI Declarations January 4, 2019 View PDF
Lenvatinib (Lenvima) RCC – Clinician COI Declarations COI Declarations January 4, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 25, 2019